Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
December 14, 2022 08:30 ET
|
Dyadic International, Inc.
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...
The Top 6 Global Manufacturer and manufacturing capabilities in Antibody market 2023 | forecast to a readjusted size of USD 13230 million by 2028 with a CAGR of 5.1%
November 16, 2022 02:06 ET
|
Proficient Market Insights
Pune, Nov. 16, 2022 (GLOBE NEWSWIRE) -- "Antibody Market" research report focus on overall information that can help to take decisions on current market situation. The Antibody market report...
Compass Therapeutics to Present at Upcoming Investment Conferences
November 08, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass Therapeutics Announces $80 Million Private Placement
November 02, 2022 09:06 ET
|
Compass Therapeutics
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to...
SERB presents preclinical data showing initial efficacy of COVID-19 treatment developed with polyclonal antibody platform
October 19, 2022 08:24 ET
|
SERB Pharmaceuticals
Washington D.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals today announces preclinical data demonstrating initial efficacy of a new polyclonal, ovine fragment antibody (Fab) developed...
Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)
October 11, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
$18+ Bn Monoclonal Antibody Diagnostic Reagent Market - 13.5% CAGR by 2028, Globally - Rising Prevalence of Cancer and Chronic Diseases, Extensive R&D Efforts to Develop Novel Therapies, Presence of Strong Pipeline of Drugs Under Trial
October 03, 2022 06:55 ET
|
The Insight Partners
New York, Oct. 03, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Monoclonal Antibody Diagnostic Reagent Market Size, Share, Revenue, Growth Strategy, Industry...
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
September 09, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass Therapeutics to Present at the 13th Annual Wedbush PacGrow Healthcare Conference
August 02, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
May 31, 2022 08:00 ET
|
Compass Therapeutics
BOSTON, May 31, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...